4LN2 Stock Chart & Stats
€17.22
€1.20(7.46%)
At close: 4:00 PM EDT
€17.22
€1.20(7.46%)
Day’s Range― - ―
52-Week Range€2.58 - €30.77
Previous CloseN/A
Volume0.00
Average Volume (3M)48.00
Market Cap
€193.24M
Enterprise Value€1.49K
Total Cash (Recent Filing)€278.61M
Total Debt (Recent Filing)€21.12M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Aug 13, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.32
Shares Outstanding57,911,892
10 Day Avg. Volume45
30 Day Avg. Volume48
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.39
Price to Sales (P/S)0.00
P/FCF Ratio-18.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.78Price Target Upside-78.02% Downside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)-0.47
Revenue Forecast (FY)€98.53M
Bulls Say, Bears Say
Bulls Say
Pivotal Phase 3 EfficacyStatistically significant Phase 3 efficacy provides durable clinical validation for deramiocel, strengthening the case for regulatory approval, label leverage and payer discussions. Long‑term, a positive Phase 3 reduces scientific uncertainty and supports commercial uptake in a rare disease with limited alternatives.
In‑house Manufacturing ReadinessOwning GMP capacity gives control over supply, quality and scale economics, reducing reliance on external CDMOs and partner bottlenecks. This structural capability supports commercialization execution, inventory stockpiling once labeled, and faster scale‑up to meet market demand as uptake grows.
Cash Runway And PRV OpportunityA multi‑hundred million cash position provides durable runway to complete FDA review, prepare for launch and fund near‑term ops without immediate dilution. Potential eligibility for a transferable Priority Review Voucher adds a structural optional non‑dilutive monetization path to extend resources or fund launch activities.
Bears Say
FDA Advisory Committee SetbackA negative FDA advisory vote, while non‑binding, represents a lasting regulatory headwind that can change agency expectations, trigger additional data requests or label restrictions, and increase approval uncertainty. This materially affects long‑term launch timing, labeling scope and payer confidence.
Litigation And Repayment Risk With NS PharmaActive litigation and the prospect of repaying $50M create structural commercial and financial uncertainty. A lost or prolonged dispute could delay distribution, force Capricor to build direct commercial infrastructure sooner, increase costs, and reduce cash resources available for launch and operations.
No Revenue And Deteriorating Cash GenerationSustained negative operating cash flow and rising OPEX create a structural funding need beyond current runway. Even with existing cash, continued burn without product revenue increases reliance on capital markets or asset monetization, which can limit strategic flexibility and pressure execution over the medium term.
Capricor Therapeutics News
4LN2 FAQ
What was Capricor Therapeutics’s price range in the past 12 months?
Capricor Therapeutics lowest stock price was €2.58 and its highest was €30.77 in the past 12 months.
What is Capricor Therapeutics’s market cap?
Capricor Therapeutics’s market cap is €193.24M.
When is Capricor Therapeutics’s upcoming earnings report date?
Capricor Therapeutics’s upcoming earnings report date is Aug 13, 2026 which is today.
How were Capricor Therapeutics’s earnings last quarter?
Capricor Therapeutics released its earnings results on May 12, 2026. The company reported -€0.511 earnings per share for the quarter, missing the consensus estimate of -€0.453 by -€0.058.
Is Capricor Therapeutics overvalued?
According to Wall Street analysts Capricor Therapeutics’s price is currently Overvalued.
Does Capricor Therapeutics pay dividends?
Capricor Therapeutics does not currently pay dividends.
What is Capricor Therapeutics’s EPS estimate?
Capricor Therapeutics’s EPS estimate is -0.51.
How many shares outstanding does Capricor Therapeutics have?
Capricor Therapeutics has 57,911,892 shares outstanding.
What happened to Capricor Therapeutics’s price movement after its last earnings report?
Capricor Therapeutics reported an EPS of -€0.511 in its last earnings report, missing expectations of -€0.453. Following the earnings report the stock price went down -0.42%.
Which hedge fund is a major shareholder of Capricor Therapeutics?
Currently, no hedge funds are holding shares in DE:4LN2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Capricor Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€3.78 (-78.02% Downside)
€3.78 (-78.02% Downside)
Blogger Sentiment
Bullish
DE:4LN2 Sentiment 74%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
112.19%
Trailing 12-Months
Company Description
Capricor Therapeutics
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
4LN2 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and regulatory progress for deramiocel — statistically significant phase 3 efficacy (primary and cardiac secondary endpoints), robust long-term safety exposure, active BLA review with a clear PDUFA date, in-house manufacturing capabilities and a solid cash runway. Management also articulated a concrete commercialization plan and eligibility for a monetizable Priority Review Voucher. Offsetting these positives are notable near-term risks: an active lawsuit with NS Pharma that creates distribution uncertainty (and potential need to repay $50M), rising operating expenses and no current product revenue, manufacturing labeling constraints for an ultra-cold-chain therapy, and unresolved ASP/AMP payer complexities that could affect access. On balance, the material clinical/regulatory achievements and internal control of manufacturing and cash resources outweigh the legal and commercial execution risks, but the litigation and payer/pricing issues remain important near-term uncertainties.View all DE:4LN2 earnings summaries4LN2 Stock 12 Month Forecast
Average Price Target
€3.78
▼(-78.02% Downside)